Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled study of Sativex for spasticity due to multiple sclerosis
2004-002509-63Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Sativex arm with Placebo arm (2 arms). Primary endpoint: Mean spasticity NRS score during weeks 13 and 14. Started Feb 2005; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2004-002509-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002509-63.